Becton, Dickinson and Co. or “BD” (NYSE:BDX) shares rose 5.9% Thursday after the medical technology company reported second-quarter fiscal 2026 results that topped Wall Street estimates and raised its full-year adjusted earnings outlook.
Reports Revenue Growth And Accelerated Buyback
“We delivered a solid second quarter, with revenue, margins, and EPS all ahead of our expectations,” Chairman, CEO, and President Tom Polen said in a statement. He added that more than 90% of the company’s business delivered mid-single-digit growth.
BD reported second-quarter revenue of $4.71 billion, up 5.2% year over year and ahead of the analyst consensus estimate of $4.67 billion. Adjusted earnings came in at $2.90 per share, topping Wall Street estimates of $2.77 per share.
The company also completed a $2 billion accelerated …